Would you include midostaurin in induction and consolidation for patients with good-risk AML w/ NPM1 mutation and FLT3-ITD (<0.5)?
Answer from: Medical Oncologist at Academic Institution
Yes, in my practice I routinely include FLT3 inhibitor (midostaurin) in upfront 7 plus 3 chemotherapy for all younger fit patients with AML regardless of NPM1 status or FLT3 allelic ratio. The RATIFY trial validated the benefit of midostaurin in patients regardless of ITD allelic birder (both high a...
Sign in or Register to read more